We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+23.45%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
+$331M
Cap. Flow
+$76.5M
Cap. Flow %
4.56%
Top 10 Hldgs %
63.28%
Holding
89
New
21
Increased
18
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$12.3M
4
AMGN icon
Amgen
AMGN
+$12.2M
5
MGNX icon
MacroGenics
MGNX
+$10.6M

Top Sells

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$23.5M
2
MRK icon
Merck
MRK
+$15.8M
3
LLY icon
Eli Lilly
LLY
+$15.8M
4
INSM icon
Insmed
INSM
+$11.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.46M

Sector Composition

Rank Sector Weight
1 Healthcare 91.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
51
Kura Oncology
KURA
$793M
$3.94M 0.23%
120,677
-104,582
-46% -$3.67M
TGTX icon
52
TG Therapeutics
TGTX
$8.19B
$3.41M 0.2%
65,474
-184,927
-74% -$6.25M
MRNS
53
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.34M 0.2%
+274,027
New +$3.82M
IMTX icon
54
Immatics
IMTX
$1.23B
$3.02M 0.18%
279,532
-45,995
-14% -$485K
CALA
55
DELISTED
Calithera Biosciences, Inc
CALA
$2.46M 0.15%
25,016
+351
+1% +$30.8K
CALA
56
PUT
DELISTED
Calithera Biosciences, Inc
CALA
$1.96M 0.12%
+20,000
New +$1.75M
ZGNX
57
DELISTED
Zogenix, Inc.
ZGNX
$1.79M 0.11%
+89,579
New +$1.83M
SYBX
58
DELISTED
Synlogic
SYBX
$1.24M 0.07%
38,331
– –
FATE icon
59
Fate Therapeutics
FATE
$275M
$1.23M 0.07%
13,497
-27,903
-67% -$1.73M
KDMN
60
DELISTED
Kadmon Holdings, Inc.
KDMN
$950K 0.06%
228,893
-401,030
-64% -$1.58M
CALA
61
CALL
DELISTED
Calithera Biosciences, Inc
CALA
$860K 0.05%
+8,750
New +$767K
REPL icon
62
Replimune Group
REPL
$454M
$763K 0.05%
+20,000
New +$833K
LQDA icon
63
Liquidia Corp
LQDA
$7.72B
$436K 0.03%
147,744
-531,656
-78% -$1.95M
PDSB icon
64
PDS Biotechnology
PDSB
$37.4M
$305K 0.02%
142,635
– –
BCAB icon
65
BioAtla
BCAB
$5.34M
$102K 0.01%
+60
New +$100K
AMGN icon
66
CALL
Amgen
AMGN
$209B
– –
-59,500
Closed -$41.2M
CGEN icon
67
Compugen
CGEN
$212M
– –
-146,592
Closed -$2.38M
CYTK icon
68
PUT
Cytokinetics
CYTK
$10.6B
– –
-325,000
Closed -$7.04M
KNSA icon
69
Kiniksa Pharmaceuticals
KNSA
$6.23B
– –
-276,628
Closed -$4.24M
MRK icon
70
Merck
MRK
$322B
– –
-199,706
Closed -$15.8M
MRNA icon
71
CALL
Moderna
MRNA
$21.6B
– –
-50,000
Closed -$3.54M
NVCR icon
72
CALL
NovoCure
NVCR
$1.76B
– –
-50,000
Closed -$5.57M
NXTC icon
73
NextCure
NXTC
$20.4M
– –
-222,655
Closed -$23.5M
OVID icon
74
Ovid Therapeutics
OVID
$427M
– –
-1,097,621
Closed -$6.3M
PTGX icon
75
Protagonist Therapeutics
PTGX
$8.55B
– –
-357,769
Closed -$6.99M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2020 Portfolio in Review

As of Q4 2020, Sofinnova Investments held 89 positions worth $1.68B, up 25% from $1.35B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments deployed $76.5M of net new capital in Q4 2020, opening 21 new positions and adding to 18 existing holdings. Its largest new stake was AstraZeneca: 421,300 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Eli Lilly, an estimated $15.8M trimmed.

  • Sofinnova Investments's largest Q4 2020 buy was AstraZeneca: 421,300 shares worth $42.1M.
  • Sofinnova Investments added most to Jazz Pharmaceuticals in Q4 2020, an estimated $12.3M increase.
  • Sofinnova Investments's biggest Q4 2020 reduction was Eli Lilly, cutting an estimated $15.8M.
  • Sofinnova Investments fully exited NextCure in Q4 2020, selling an estimated $23.5M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.68B portfolio in Q4 2020.
  • Sofinnova Investments opened 21 new positions and closed 21 in Q4 2020.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.68B.

Based on Sofinnova Investments's 13F filing for Q4 2020, filed 16 Feb 2021.